Rochester, MI, USA, July 17, 2023 – Caeregen Therapeutics announced today that it has been awarded a $1.4 million Phase 2 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) and National Eye Institute (NEI) to advance the development of CTR-107 (Noregen™),...
Rochester, MI, USA and Halle, Germany, June 28, 2023 – Caeregen Therapeutics, a regenerative medicine therapeutics company and Wacker Biotech, a contract development and manufacturing organization (CDMO), will collaborate on the development and production of CTR-107 (Noregen™), a novel regenerative therapeutic for the treatment of retinal-related...
It is with great sadness we announce the passing of Dr. Michael T. Trese, co-founder and Chief Technology Officer of Caeregen Therapeutics. Dr. Trese was one of the pioneers, leading innovators, and pillars of the retinal research community, spearheading advancements in preventing and treating blindness in...
First potential FEVR therapy to obtain U.S. FDA Rare Pediatric Disease Designation Designation provides Noregen™ Rare Pediatric Disease Priority Review Voucher Eligibility Follows earlier Orphan Drug Designations in FEVR by both US FDA and EC EMA Caeregen Therapeutics today announced the U.S. Food and Drug Administration (FDA) designated Noregen™ for treatment...
Update in Understanding and Managing FEVR New research approaches and potential therapeutics are moving the field toward improved care for these patients. By Kimberly A. Drenser, MD, PhD April 2022 Familial exudative vitreoretinopathy (FEVR) is a relatively rare hereditary disease that remains poorly understood. Although there’s a lack of...
Data presented on promising activity of Noregen™, first potential regenerative therapy for retinal diseasesFollows 1Q2022 U.S. FDA and EU EMA Orphan Drug Designation (ODD) for Noregen™ in Familial Exudative Vitreoretinopathy (FEVR) May 3, 2022, Denver, CO and Rochester, MI – Caeregen Therapeutics, LLC, a Michigan-based, regenerative medicine therapeutics company...
A Novel Regenerative Therapy For The Treatment Of Familial Exudative Vitreoretinopathy (FEVR) First potential FEVR therapy to obtain U.S. Food and Drug Administration Orphan Drug DesignationFollows Orphan Medicinal Product Designation by European Commission based European Medicines Agency Committee for Orphan Medicinal Products Positive Opinion January 27, 2022,...
2021 Laureate Award Recognizes Exceptional Contributions in Overcoming Vision Loss November 11, 2021, Rochester, MI and New Orleans, LA – Caeregen Therapeutics, LLC, a Michigan-based, regenerative medicine therapeutics company, today announced that company co-founder Dr. Michael T. Trese, received the prestigious Laureate Award from the American Academy...
Advancing treatments for retinal-related vision loss and other neurosensory diseases Rochester, MI and Chapel Hill, NC, August 12, 2021 – Retinal Solutions, LLC, a Michigan-based, regenerative medicine therapeutics company, today announced it has changed its name to Caeregen Therapeutics, LLC. The progression into pharmaceutical development of Noregen™, the...
Wnt-signaling has been implicated in retinal development. The aim of this study was to investigate the possibility of improving retinal vasculature in an animal model of retinopathy by activating Wnt-signaling...